Infectious Diseases

  • CholeraGarde® and ETEC Vaccine: The bacterial vaccines programs are innovative vaccines that address health care needs on a global basis. Utilizing its live, attenuated Cholera-vectored delivery technologies allows for a new generation of vaccines that have an ideal product profile: safe, effective, oral, single-dose, and rapidly protective.

    The lead program, CholeraGarde®, is a vaccine against Cholera that has demonstrated safety, immunogenicity, and protection from challenge with live V. cholerae in Phase 2 trials. The International Vaccine Institute (“IVI”) is conducting additional Phase 2 clinical trials with CholeraGarde® under a clinical trials agreement.

    In addition, Celldex has developed a bacterial vaccine against enterotoxigenic E. coli (“ETEC”). ETEC is a major cause of enteric disease among travelers, military personnel and those who live in developing countries where the disease is endemic. Market research studies conducted with travel medicine clinics have shown a strong preference for a combined vaccine compared to either ETEC or cholera vaccines given separately. A Phase 1 study with the ETEC vaccine has been initiated through the support of the Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH).

    Celldex recently entered into a licensing agreement with Vaccine Technologies, Inc. (VTI) to develop and commercialize Celldex's CholeraGarde® and ETEC vaccine programs.
  • Ty800 Vaccine for Typhoid Fever: A third bacterial vaccine program is exemplified by an oral typhoid fever vaccine, Ty800, for the travelers’ market and global health needs. The Ty800 vaccine is designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S. typhi. Recent Phase 2 studies have demonstrated safety and immunogenicity of Ty800.
  • CDX-2401 – Prevention of HIV Infection: Celldex is developing an APC Targeting prophylactic vaccine aimed at providing protection from infection with HIV, the virus known to cause AIDS. CDX-2401 is a fusion protein consisting of a fully human monoclonal antibody with specificity for the dendritic cell receptor, DEC-205 linked to an HIV antigen. This program is in a Bill & Melinda Gates Foundation funded partnership with collaborators at The Rockefeller University in New York City, and has shown in model systems that protective immunity can be induced with such a vaccine. Preclinical studies and manufacturing development are in progress and Celldex plans to initiate Phase 1 clinical studies in 2009.

For citations related to Bacterial Vaccines click here and CDX-2401 click here

Print Page